Teva reports positive topline results from a Phase 2a study of its anti-IL-15 monoclonal antibody, TEV ’408, in people with celiac disease. The company says a single subcutaneous dose leads to statistically significant and clinically meaningful prevention of gluten-induced intestinal damage compared with placebo.
Teva also states that TEV ’408 is well tolerated, with no safety signals observed to date. The Seeking Alpha and Financial Post coverage both frame the results as supportive of Teva’s pipeline-in-a-product strategy, emphasizing that the celiac disease data add to momentum around the broader development program. Neither outlet provides detailed methodology, sample size, endpoints, or longer-term follow-up in the excerpts provided, so those specifics are not confirmed across the reports.
Across the sources, the emphasis differs mainly in phrasing: Seeking Alpha presents the findings through a transcript-style summary, while Financial Post highlights “further validating” the program potential. Both agree on the core claim: TEV ’408 shows favorable topline efficacy and tolerability after a single dose in the Phase 2a celiac study.
